On 1 August 2016, JSC Olainfarm rang the closing bell of a trading session at the Nasdaq MarketSite studio in New York Times Square. The festive ceremony was attended by the Chairman of the Board of JSC Olainfarm Valērijs Maligins and the Member of the Board Salvis Lapiņš, as well as the Chairwoman of the Board of Nasdaq Riga Daiga Auziņa-Melalksne.
To celebrate a decade of Baltic Market Awards (BMA), at the beginning of this year, JSC Olainfarm earned the special prize “Best achievement in 10 years” for the highest stock price increase and growth in the opinion of BMA, and received an invitation to ring the closing bell of a trading session at Nasdaq MarketSite studio in Times Square.
Over the last decade, JSC Olainfarm has unwaveringly worked to improve the performance of investor relations, by organising countless virtual conferences of investors, visiting presentations in the Baltic and Nordic states, all the while ensuring an open and transparent communication with shareholders and the enterprise on the whole. The results of JSC Olainfarm in the assessment of BMA since the very first evaluation in 2006 have improved by 25%, whereas the price of stocks over 10 years has grown by 448%. Olainfarm has become a benchmark for other enterprises quoted on the Nasdaq Baltic stock exchange, as it has managed to combine accountable investor relations with substantial profits for investors.
Photo: © 2016 Nasdaq, Inc.
JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 35 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.
Head of PR
mobile: (+371) 26 377 286